Literature DB >> 18085615

The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse.

S L Preston1, S J Leedham, D Oukrif, M Deheregoda, R A Goodlad, R Poulsom, M R Alison, N A Wright, M Novelli.   

Abstract

UNLABELLED: The morphological changes associated with the adenoma-carcinoma sequence are well documented in the colorectum. Small intestinal carcinogenesis is thought to progress through a similar adenoma-to-carcinoma pathway, but there is a relative dearth of studies examining the associated morphological changes. The best-known mouse model of intestinal neoplasia, the multiple intestinal neoplasia (Min) mouse, has been criticized as a genetic model of intestinal neoplasia, as the majority of its tumours occur in the small intestine. We examined pancreatico-duodenal resection specimens from seven familial adenomatous polyposis (FAP) patients. Serial sections of these were stained with haematoxylin and eosin for beta-catenin and its downstream target CD44, for BMPR1a, lysozyme, carbonic anhydrase II, and with MIB-1. Individual dysplastic crypts were isolated and mutations in the FAP (APC) gene compared between the top and bottom of the crypt. We found that: (a) duodenal microadenomas are extremely common in FAP patients; (b) these grow in the core of duodenal villi, forming lesions similar to those described in the Min mouse; (c) many lesions arise as monocryptal adenomas and grow by a process of crypt fission and branching; (d) migrating adenomatous cells lose their dysplastic phenotype as they migrate up the crypt villous axis; and (e) Paneth cells lose positional information. IN
CONCLUSION: (a) the morphological similarity of adenomas in the Min mouse and human suggest the Min mouse is a good model of FAP; (b) duodenal adenomas in FAP originate in monocryptal adenomas and follow the 'bottom-up' rather than the 'top-down' model of morphogenesis; (c) early microadenomas show evidence of cellular differentiation; (d) defects in the positioning of Paneth cells suggests disruption of the EphB2:EphB3 receptor system. Copyright (c) 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18085615     DOI: 10.1002/path.2294

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

1.  Functional Cftr in crypt epithelium of organotypic enteroid cultures from murine small intestine.

Authors:  Jinghua Liu; Nancy M Walker; Matthew T Cook; Akifumi Ootani; Lane L Clarke
Journal:  Am J Physiol Cell Physiol       Date:  2012-03-07       Impact factor: 4.249

2.  Transgenic expression of VEGF in intestinal epithelium drives mesenchymal cell interactions and epithelial neoplasia.

Authors:  Amelie Boquoi; Rodrigo Jover; Tina Chen; Marieke Pennings; Greg H Enders
Journal:  Gastroenterology       Date:  2008-11-01       Impact factor: 22.682

3.  Characterization of Colorectal Cancer Development in Apc (min/+) Mice.

Authors:  ILKe Nalbantoglu; Valerie Blanc; Nicholas O Davidson
Journal:  Methods Mol Biol       Date:  2016

4.  Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin.

Authors:  Subapriya Rajamanickam; Balaiya Velmurugan; Manjinder Kaur; Rana P Singh; Rajesh Agarwal
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

5.  EPH-EPHRIN in human gastrointestinal cancers.

Authors:  Haruhiko Sugimura; Jian-Dong Wang; Hiroki Mori; Masaru Tsuboi; Kiyoko Nagura; Hisaki Igarashi; Hong Tao; Ritsuko Nakamura; Hiroko Natsume; Tomoaki Kahyo; Kazuya Shinmura; Hiroyuki Konno; Yasushi Hamaya; Shigeru Kanaoka; Hideki Kataoka; Xiao-Jun Zhou
Journal:  World J Gastrointest Oncol       Date:  2010-12-15

6.  Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway.

Authors:  Subapriya Rajamanickam; Manjinder Kaur; Balaiya Velmurugan; Rana P Singh; Rajesh Agarwal
Journal:  Pharm Res       Date:  2009-09-25       Impact factor: 4.200

7.  The stem cells of small intestinal crypts: where are they?

Authors:  C S Potten; R Gandara; Y R Mahida; M Loeffler; N A Wright
Journal:  Cell Prolif       Date:  2009-09-28       Impact factor: 6.831

8.  Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.

Authors:  Altaf Mohammed; Naveena B Janakiram; Misty Brewer; Krishna Vedala; Vernon E Steele; Chinthalapally V Rao
Journal:  Neoplasia       Date:  2013-05       Impact factor: 5.715

9.  Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032.

Authors:  Amelie Boquoi; Tina Chen; Greg H Enders
Journal:  Cancer Prev Res (Phila)       Date:  2009-09-01

10.  Cell and tissue polarity in the intestinal tract during tumourigenesis: cells still know the right way up, but tissue organization is lost.

Authors:  Aliya Fatehullah; Paul L Appleton; Inke S Näthke
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-09-23       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.